Both Avenue Therapeutics Inc. (NASDAQ:ATXI) and Canopy Growth Corporation (NYSE:CGC) compete on a level playing field in the Drug Manufacturers – Other industry. We will evaluate their performance with regards to analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics Inc.	N/A	0.00	23.87M	-2.36	0.00
Canopy Growth Corporation	N/A	0.00	N/A	-1.79	0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Avenue Therapeutics Inc. and Canopy Growth Corporation.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Avenue Therapeutics Inc. and Canopy Growth Corporation.

	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics Inc.	0.00%	-261.3%	-183.1%
Canopy Growth Corporation	0.00%	0%	0%

Institutional and Insider Ownership

Roughly 2.1% of Avenue Therapeutics Inc. shares are held by institutional investors while 0% of Canopy Growth Corporation are owned by institutional investors. 12% are Avenue Therapeutics Inc.’s share held by insiders.

Performance

Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Avenue Therapeutics Inc.	-5.37%	20.54%	47.16%	15.46%	22.48%	36.19%
Canopy Growth Corporation	-7.54%	-32.67%	-40.63%	4.97%	117.84%	31.13%

For the past year Avenue Therapeutics Inc.’s stock price has bigger growth than Canopy Growth Corporation.

Summary

Canopy Growth Corporation beats Avenue Therapeutics Inc. on 4 of the 6 factors.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. Its product candidate is IV Tramadol for the treatment of post-operative pain. The company was founded in 2015 and is based in New York, New York. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.